Histamine metabolic process

Across TCGA pan-cancer cohorts, RNA activity of the Histamine metabolic process pathway is associated with patient survival in 24 of 34 cancer lineages. Pathway activity is summarized from the expression of its 6 member genes.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher Histamine metabolic process pathway activity is associated with poorer overall survival. In most high-consensus cancer types, elevated pathway activity shows an unfavorable survival association, although some cancer types, such as UVM and BLCA, show the opposite pattern, with higher activity associated with better survival.

STAD, UVM, and LUSC are the cancer lineages in which this pathway most reproducibly stratifies patient survival.

Pathway-activity survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 represent the survival AUCs for the high- and low-pathway-activity groups, respectively. The group with the lower AUC is interpreted as having poorer survival. The reported p-values are derived from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Quartile	III,IV	0.356	0.695	<.001	81	view →
UVM	OS	Median	All	0.982	0.737	<.001	48	view →
LUSC	DFS	Tertile	III,IV	0.365	0.781	<.001	43	view →
THYM	OS	Quartile	All	0.908	1.000	.006	41	view →
BLCA	DFS	Median	All	0.453	0.265	.001	38	view →
CESC	OS	Median	All	0.819	0.914	.005	36	view →
SKCM	OS	Median	All	0.261	0.413	<.001	30	view →
UCEC	DFS	Quartile	IV	0.283	0.853	.014	28	view →
MESO	OS	Quartile	All	0.398	0.640	.008	24	view →
LAML	DFS	Median	All	0.678	0.477	.002	18	view →
SCLC	DFS	Quartile	All	0.451	0.804	.008	17	view →
COAD	DFS	Median	All	0.717	0.851	.008	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

GO:0001692–STAD (OS)

Open the STAD breakdown →